LONDON--(BUSINESS WIRE)--Regulatory News:
Ares Allergy Holdings plc (Euronext:STAGR) today announces that it is changing its name to Stallergenes Greer plc. This decision was approved by the shareholders during the Extraordinary General Meeting held in Paris today.
Fereydoun Firouz, Chairman and Chief Executive Officer of Ares Allergy Holdings plc, said:
“We are excited to execute the first element in the transformation of our company, with the swift implementation of one clear, unified, global brand. As employees, we feel engaged and energized by this new identity. The name of Stallergenes Greer is a natural fit for our newly combined company, as it allows us to harness and build on the strength of both companies and it accurately embodies the value proposition we offer to all our stakeholders.”
The name change is effective from today, 27 October 2015 and will be progressively implemented globally.
As previously announced, Stallergenes Greer plc will hold a webcast business update, hosted by Chairman and CEO, Fereydoun Firouz, on 5 November 2015. This update will cover the company’s corporate strategy and short to mid term priorities.
ABOUT STALLERGENES GREER PLC
Headquartered in London (UK), Stallergenes Greer plc is a global company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).
Name: Stallergenes Greer
ISIN: GB00BZ21RF93 1 - Ticker: STAGR
ICB classification: 4577
Market: Euronext Paris regulated market
Additional information is available at http://www.stallergenesgreer.com